The Denmark-based company announced Wednesday it had received a Complete Response Letter for dasiglucagon, which it was proposing for the ultra-rare genetic disease congenital hyperinsulinism, due to the timing of a third-party manufacturing facility reinspection. In an initial visit, the FDA had flagged deficiencies in a third-party contract manufacturer, which the company claims had been resolved by the time of a reinspection in August/September 2024
Yes, and this is one of the most synergistic combinations available
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC Updated March 26, 2026 HEAD-TO-HEAD HOW THEY WORK (AND WHY IT MATTERS) Both medications mimic gut hormones that your body produces naturally after eating
The complete retatrutide dose schedule breaks down each step in granular detail
Using the BPC-157 calculator and TB-500 calculator ensures appropriate dosing when stacking